Potassium chloride

Identification

Summary

Potassium chloride is a potassium salt used to treat hypokalemia.

Brand Names
Bi-peglyte, Bss, Bss Ophthalmic Solution, Cardioplegic, Citrasate, Colyte, Dextrose and Electrolyte No. 75, Eye Stream, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Glycerolyte 57, Golytely, H.E.L.P.bicel, Hemosate Ultra, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S pH 7.4, Isoplate, K 45, K-tab, Klor-con, Lactated Ringers, Moviprep, Naturalyte, Normosol-R, Nulytely, Nxstage Pureflow, Olimel, Peglyte, Periolimel, Phoxillum, Physiolyte, Physiosol, Plasma-lyte, Plasma-lyte 148, Plasma-lyte 148 In 5 % Dextrose, Plasma-lyte R, Plasmalyte A, Plegisol, Plenvu, Prismasol, Procalamine 3, Ringers, Selectbag One, Tis-U-sol
Generic Name
Potassium chloride
DrugBank Accession Number
DB00761
Background

A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
Thumb
Weight
Average: 74.551
Monoisotopic: 73.932559568
Chemical Formula
ClK
Synonyms
  • Chlorid draselny
  • Chloride of potash
  • Kaliumchlorid
  • KCl
  • Monopotassium chloride
  • Muriate of potash
  • Potassium chloride
  • Sylvite
External IDs
  • B1653
  • E 508
  • E-508
  • INS NO.508
  • INS-508
  • NSC-77368

Pharmacology

Indication

For use as an electrolyte replenisher and in the treatment of hypokalemia.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.

Mechanism of action

Supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.

TargetActionsOrganism
USolute carrier family 12 member 2Not AvailableHumans
USolute carrier family 12 member 1
binder
Humans
USolute carrier family 12 member 5Not AvailableHumans
USolute carrier family 12 member 6Not AvailableHumans
USolute carrier family 12 member 7Not AvailableHumans
USolute carrier family 12 member 4Not AvailableHumans
Absorption

Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Potassium is a normal dietary constituent and, under steady-state conditions, the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake.

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, of if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result. It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirPotassium chloride may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcebutololPotassium chloride may increase the hyperkalemic activities of Acebutolol.
AceclofenacPotassium chloride may increase the hyperkalemic activities of Aceclofenac.
AcemetacinPotassium chloride may increase the hyperkalemic activities of Acemetacin.
AcetaminophenAcetaminophen may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidPotassium chloride may increase the hyperkalemic activities of Acetylsalicylic acid.
AclidiniumThe risk or severity of gastrointestinal ulceration can be increased when Aclidinium is combined with Potassium chloride.
AcrivastinePotassium chloride may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Take with a full glass of water.
  • Take with food. This reduces gastrointestinal irritation.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Potassium cationionic295O53K15224203-36-9NPYPAHLBTDXSSS-UHFFFAOYSA-N
Chloride ionionicQ32ZN4869816887-00-6VEXZGXHMUGYJMC-UHFFFAOYSA-M
Product Images
International/Other Brands
Kaon Cl / Kaon-CL 10 / Micro-K / Sando-K / Slow-K
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Chlorure de potassium ProampInjection, solution, concentrate0.15 g/1mLIntravenousLaboratoire Aguettant2018-07-31Not applicableUS flag
EpiklorPowder, for solution1.5 g/1.77gOralEpic Pharma, LLC2010-02-012013-10-01US flag
Epiklor/25Powder, for solution1.875 g/2.21gOralEpic Pharma, LLC2010-02-012013-09-01US flag
HUMCO Potassium Chloride 10 PercentLiquid100 mg/1mLOralHumco Holding Group. Inc.1979-01-012015-12-31US flag
K + 45Liquid251.6 g / LHemodialysisBaxter Laboratories1990-12-31Not applicableCanada flag
K C1-rougierLiquid750 mg / 15 mLOralRougier Pharma Division Of Ratiopharm Inc1967-12-311999-09-27Canada flag
K Lor Granules 20meqPowder, for solution1.5 g / 3 gOralAbbott1979-12-312008-06-06Canada flag
K-durTablet, extended release1.5 gOralMerck Ltd.1989-12-312014-12-04Canada flag
K-durTablet, extended release750 mg/1OralMerck Sharp & Dohme Limited1986-06-132008-10-31US flag
K-durTablet, extended release1500 mg/1OralMerck Sharp & Dohme Limited1986-06-132008-10-31US flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Klor Con MTablet, extended release750 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-11-20Not applicableUS flag
Klor Con MTablet, extended release1500 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-11-20Not applicableUS flag00245 0058 01 nlmimage10 bb345de2
Klor-ConTablet, extended release1500 mg/1OralApace Packaging2000-08-092014-09-30US flag
Klor-conPowder, for solution1.5 g/1OralUpsher-Smith Laboratories, LLC2017-10-23Not applicableUS flag
Klor-Con MTablet, extended release750 mg/1OralMc Kesson Contract Packaging2011-12-072017-09-30US flag
Klor-Con MTablet, extended release1500 mg/1OralAphena Pharma Solutions - Tennessee, Inc.2011-01-182019-05-17US flag
Klor-con MTablet, extended release1500 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-09-01Not applicableUS flag
Klor-con MTablet, extended release1500 mg/1OralSandoz Inc.2011-01-182021-10-31US flag
Klor-Con MTablet, extended release1500 mg/1OralUpsher-Smith Laboratories, Inc.2011-01-182015-12-31US flag0245 005820180913 8702 ryadba
Klor-con MTablet, extended release1500 mg/1OralCardinal Health2014-09-012021-05-31US flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ADDI-KTablet, extended release750 mgOralบริษัท ดีเคเอสเอช (ประเทศไทย) จำกัด2010-05-17Not applicableThailand flag
APO-K TABLET 600 mgTablet, film coated600 mgOralPHARMAFORTE SINGAPORE PTE LTD1991-08-19Not applicable
APO-K TABLET 600MG (S/R)TabletOralPHARMAFORTE (MALAYSIA) SDN. BHD.2020-09-08Not applicableMalaysia flag
Hi Potency Potassium ChlorideTablet, extended release500 mgOralSwiss Herbal Remedies Ltd.1997-02-242001-08-02Canada flag
Kaochlor-20Solution3 g / 15 mLOralPfizer Canada Ulc1995-12-312006-08-02Canada flag
Micro-K-10 Extencaps Src 750mgCapsule, extended release750 mg / srcOralWyeth Ayerst Canada Inc.1994-12-312003-07-28Canada flag
POTASSIUM CHLORIDE INJECTION - HIGHLY CONCENTRATED (100 mEq/l)Injection746 mg/100mlIntravenousBAXTER HEALTHCARE (ASIA) PTE LTD2001-05-29Not applicable
POTASSIUM CHLORIDE INJECTION - HIGHLY CONCENTRATED (200 mEq/l)Injection746 mg/50mlIntravenousBAXTER HEALTHCARE (ASIA) PTE LTD2001-06-21Not applicable
POTASSIUM CHLORIDE INJECTION - HIGHLY CONCENTRATED (400 mEq/l)Injection1.49 g/50mlIntravenousBAXTER HEALTHCARE (ASIA) PTE LTD2001-06-21Not applicable
POTASSIUM CHLORIDE MIXTURE 500 mg/5 mlSolution500 mg/5mlOralBEACONS PHARMACEUTICALS PTE. LTD.1995-11-11Not applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
(20 Mmol/l) Potassium Chloride In 3.3% Dextrose and 0.3% Sodium Chloride Injection USPPotassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (3.3 g / 100 mL) + Sodium chloride (300 mg / 100 mL)SolutionIntravenousBaxter Laboratories1978-12-31Not applicableCanada flag
(20 Mmol/l) Potassium Chloride In 5% Dextrose and 0.9% Sodium Chloride Injection USPPotassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Sodium chloride (900 mg / 100 mL)SolutionIntravenousBaxter Laboratories1990-12-31Not applicableCanada flag
(20 Mmol/l) Potassium Chloride In 5% Dextrose Injection USPPotassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL)SolutionIntravenousBaxter Laboratories1989-12-31Not applicableCanada flag
(20mmol/l) Potassium Chloride In 0.9% Sodium Chloride Injection USPPotassium chloride (150 mg / 100 mL) + Sodium chloride (900 mg / 100 mL)SolutionIntravenousBaxter Laboratories1989-12-31Not applicableCanada flag
(20mmol/l) Potassium Chloride In 5% Dextrose and 0.2% Sodium Chloride Injection USPPotassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Sodium chloride (200 mg / 100 mL)SolutionIntravenousBaxter Laboratories1989-12-312016-07-15Canada flag
(20mmol/l) Potassium Chloride In 5% Dextrose and 0.45% Sodium Chloride Injection USPPotassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Sodium chloride (450 mg / 100 mL)SolutionIntravenousBaxter Laboratories1989-12-31Not applicableCanada flag
(40 Mmol/l) Potassium Chloride In 0.9% Sodium Chloride Injection USPPotassium chloride (300 mg / 100 mL) + Sodium chloride (900 mg / 100 mL)LiquidIntravenousBaxter Laboratories1989-12-31Not applicableCanada flag
(40 Mmol/l) Potassium Chloride In 5% Dextrose Injection USPPotassium chloride (300 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL)SolutionIntravenousBaxter Laboratories1989-12-31Not applicableCanada flag
(40 Mmols/l) Potassium Chloride In Lactated Ringer's Injection USPPotassium chloride (328 mg / 100 mL) + Calcium chloride (20 mg / 100 mL) + Sodium lactate (310 mg / 100 mL) + Sodium chloride (600 mg / 100 mL)SolutionIntravenousBaxter Laboratories2002-12-112016-07-15Canada flag
(40mmol/l) Potassium Chloride In 3.3% Dextrose and 0.3% Sodium Chloride Injection USPPotassium chloride (300 mg / 100 mL) + Dextrose, unspecified form (3.3 g / 100 mL) + Sodium chloride (300 mg / 100 mL)SolutionIntravenousBaxter Laboratories1978-12-31Not applicableCanada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
BIOFLEKS %5 DEKSTROZ RINGER LAKTAT 500 ML SOLUSYON (PVC TORBA) SETSIZPotassium chloride (0.03 %) + Calcium chloride (0.02 %) + Dextrose, unspecified form (5 %) + Sodium lactate (0.31 %) + Sodium chloride (0.6 %)SolutionIntravenousOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
BIOFLEKS %5 DEKSTROZ RINGER LAKTAT ENJEKTABL SOL (PVC TORBA) 1000 ML SETLIPotassium chloride (0.03 %) + Calcium chloride (0.02 %) + Dextrose, unspecified form (5 %) + Sodium lactate (0.31 %) + Sodium chloride (0.6 %)SolutionIntravenousOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
BIOFLEKS %5 DEKSTROZ RINGER LAKTAT ENJEKTABL SOL (PVC TORBA) 1000 ML SETSIZPotassium chloride (0.03 %) + Calcium chloride (0.02 %) + Dextrose, unspecified form (5 %) + Sodium lactate (0.31 %) + Sodium chloride (0.6 %)SolutionIntravenousOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
BIOFLEKS %5 DEKSTROZ RINGER LAKTAT ENJEKTABL SOL (PVC TORBA) 500 ML SETLIPotassium chloride (0.03 %) + Calcium chloride (0.02 %) + Dextrose, unspecified form (5 %) + Sodium lactate (0.31 %) + Sodium chloride (0.6 %)SolutionIntravenousOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 1000 ML SETLIPotassium chloride (10 mEq/L) + D-glucose monohydrate (5 %)SolutionIntravenousOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 1000 ML SETSIZPotassium chloride (10 mEq/L) + D-glucose monohydrate (5 %)SolutionIntravenousOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 500 ML SETLIPotassium chloride (10 mEq/L) + D-glucose monohydrate (5 %)SolutionIntravenousOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 500 ML SETSIZPotassium chloride (10 mEq/L) + D-glucose monohydrate (5 %)SolutionIntravenousOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
BIOFLEKS 20MEQ/L KCL%5DEK 100 ML SOLUSYON SETSIZPotassium chloride (20 mEq/L) + D-glucose monohydrate (5 %)SolutionIntravenousOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
BIOFLEKS 20MEQ/L KCL%5DEK 1000 ML SOLUSYON SETSIZPotassium chloride (20 mEq/L) + D-glucose monohydrate (5 %)SolutionIntravenousOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

ATC Codes
A12BA51 — Potassium chloride, combinationsB05XA01 — Potassium chlorideA12BA01 — Potassium chloride
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as alkali metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal salts
Sub Class
Alkali metal chlorides
Direct Parent
Alkali metal chlorides
Alternative Parents
Inorganic chloride salts
Substituents
Alkali metal chloride / Inorganic chloride salt / Inorganic salt
Molecular Framework
Not Available
External Descriptors
potassium salt, inorganic chloride (CHEBI:32588)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
660YQ98I10
CAS number
7447-40-7
InChI Key
WCUXLLCKKVVCTQ-UHFFFAOYSA-M
InChI
InChI=1S/ClH.K/h1H;/q;+1/p-1
IUPAC Name
potassium chloride
SMILES
[Cl-].[K+]

References

Synthesis Reference

Fritz Hagedorn, Gerd Peuschel, Arno Singewald, "Method for the production of potassium chloride with K.sub.2 O content of more than 55 weight percent." U.S. Patent US5057208, issued July, 1955.

US5057208
General References
Not Available
KEGG Drug
D02060
PubChem Compound
4873
PubChem Substance
46506038
ChemSpider
4707
RxNav
8591
ChEBI
32588
ChEMBL
CHEMBL1200731
Therapeutic Targets Database
DAP000828
PharmGKB
PA451055
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Potassium_chloride
FDA label
Download (632 KB)
MSDS
Download (72.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentHypovolaemia1
4CompletedNot AvailableColonoscopy1
4CompletedBasic ScienceBlood Pressures / High Blood Pressure (Hypertension)1
4CompletedBasic ScienceConstipation - Functional / Irritable Bowel Syndrome Characterized by Constipation1
4CompletedDiagnosticColon Adenomas / Colon Lesions / Colon Polyps1
4CompletedScreeningColorectal Carcinoma (CRC)1
4CompletedTreatmentArrhythmia / Hypokalemia1
4CompletedTreatmentAtrial Fibrillation / Flutter, Atrial1
4CompletedTreatmentBowel Preparation for Colonoscopy1
4CompletedTreatmentCesarean Sections / Hypotension / Pregnant State / Spinal Anaesthesia1

Pharmacoeconomics

Manufacturers
  • Novo nordisk inc
  • Savage laboratories inc div altana inc
  • Kv pharmaceutical co
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
  • Abraxis pharmaceutical products
  • Akorn inc
  • App pharmaceuticals llc
  • B braun medical inc
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp
  • Gd searle llc
  • Hospira inc
  • International medication system
  • Eli lilly and co
  • Luitpold pharmaceuticals inc
  • Miles laboratories inc
  • Pharma serve inc sub torigian laboratories
  • Watson laboratories inc
  • Future pak ltd
  • Upsher smith laboratories inc
  • Apothecon inc div bristol myers squibb
  • Abbott laboratories pharmaceutical products div
  • Copley pharmaceutical inc
  • Eurand america inc
  • Schering corp
  • Novartis pharmaceuticals corp
  • Upsher-Smith Laboratories Inc.
Packagers
  • Abbott Laboratories Ltd.
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Alaven Pharmaceutical
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apace Packaging
  • Apothecon
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Century Pharmaceuticals Inc.
  • Chemrich Laboratories Inc.
  • Comprehensive Consultant Services Inc.
  • Corvit Pharmaceuticals
  • Coupler Enterprises Inc.
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Edwards Pharmaceuticals
  • Epic Pharma LLC
  • Ethex Corp.
  • Eurand Pharmaceuticals Inc.
  • Forest Pharmaceuticals
  • General Injectables and Vaccines Inc.
  • H and H Laboratories
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Humco
  • John Ross Chemical Ltd.
  • Kaiser Foundation Hospital
  • KV Pharmaceutical Co.
  • Laboratoires Upsa
  • Lake Erie Medical and Surgical Supply
  • Legacy Pharmaceuticals Packaging LLC
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Mckesson Corp.
  • Mead Johnson and Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neighborcare Repackaging Inc.
  • Neuman Distributors Inc.
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmaceutical Packaging Center
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacia Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Qualitest
  • Rebel Distributors Corp.
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sandoz
  • Savage Labs
  • Schering Corp.
  • Schering-Plough Inc.
  • Southwood Pharmaceuticals
  • Summit Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Ther-Rx Corp.
  • Tower Laboratories Ltd.
  • Tya Pharmaceuticals
  • United Research Laboratories Inc.
  • Upsher Smith Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Vintage Pharmaceuticals Inc.
  • Warrick Pharmaceuticals Corp.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage Forms
FormRouteStrength
LiquidIntravenous
InjectionIntravenous50 g/L
SolutionHemodialysis
SolutionHemodialysis0.257 g/1000ml
Tablet, extended releaseOral750 mg
SolutionIrrigation; Parenteral
Powder, for solutionIntraocular
SolutionIntraocular
Tablet, film coatedOral600 mg
SolutionOphthalmic
Kit; powder, for solution; tablet, delayed releaseOral
Powder, for solutionOral1.685 g
SolutionHemodialysis; Intravenous0.187 g/L
Kit; solutionIntraocular
LiquidOphthalmic
SolutionIntra-arterial
Injection, solution, concentrateIntravenous0.15 g/1mL
SolutionIntravenous1.49 g
SolutionParenteral0.149 g
SolutionParenteral1.49 g
SolutionIntravenous20 mEq/mL
SolutionIntravenous10 g
SolutionIntravenous1.491 g
Powder, for solutionNasogastric
SolutionIntravenous0.27 g/1000ml
InjectionIntravenous0.027 g/100ml
InjectionIntravenous270 mg/l
SolutionIrrigation
InjectionOther
InjectionOther16 mmol/20ml
InjectionIntravenous
SolutionOphthalmic0.02 %
SolutionIntravenous4.21 g/1000ml
Tablet, effervescentOral
Granule, for solutionOral
SolutionIntrathecal
InjectionIntrathecal
SolutionParenteral
SolutionIntravenous; Subcutaneous
PowderOral
Powder, for solutionOral1.5 g/1.77g
Powder, for solutionOral1.875 g/2.21g
EmulsionParenteral
Granule, for solutionOral64 g
Solution, concentrateHemodialysis
SolutionIntravenous0.15 g/1000ml
Aerosol, sprayOral
SolutionOther57 g/100ml
SolutionUnknown
SolutionExtracorporeal
Powder, for solutionNasogastric; Oral
SolutionHemodialysis7.77 g/l
SolutionHemodialysis6.47 g/l
SolutionHemodialysis8.46 g/l
SolutionHemodialysis8.8 g/l
SolutionHemodialysis8.85 g/l
SolutionHemodialysis9.74 g/l
LiquidHemodialysis
SolutionHemodialysis6.77 g/l
Tablet, extended releaseOral500 mg
SolutionOral
SolutionConjunctival; Ophthalmic
LiquidOral100 mg/1mL
PatchTopical
Solution, concentrateIntravenous
InjectionParenteral746 mg
InjectionParenteral1.49 g
InjectionParenteral2.24 g
InjectionParenteral2.98 g
InjectionParenteral
LiquidIntraocular
SolutionIntravenous
LiquidHemodialysis251.6 g / L
LiquidOral750 mg / 15 mL
Powder, for solutionOral1.5 g / 3 g
Tablet, extended releaseOral1.5 g
ElixirOral10 g
Powder, for solutionOral1.86 g / 7.8 g
TabletOral900 mg
LiquidOral20 meq/15mL
LiquidOral40 meq/15mL
Tablet, film coated, extended releaseOral1500 mg/1
Tablet, film coated, extended releaseOral750 mg/1
SolutionIntravenous74.5 mg
Injection, emulsionIntravenous
InjectionIntravenous2.3 g/1000ml
InjectionIntravenous1.6 g/l
Capsule, extended releaseOral600 mg
Tablet, extended releaseOral750 mg / tab
SolutionIntravenous
Injection, solution, concentrateIntravenous
SolutionOral10 %
SolutionOral3 g / 15 mL
Powder, for solutionOral1.5 g / pck
Tablet, extended releaseOral600 MG
Tablet, sugar coatedOral
SolutionOral200 mg / mL
Powder, for solutionOral1.875 g/1
Powder, for solutionOral20 meq/1
Tablet, extended releaseOral750 mg/1
Tablet, extended releaseOral10 meq/1
Tablet, extended releaseOral1125 mg/1
Tablet, extended releaseOral20 meq/1
Tablet, film coated, extended releaseOral
InjectionIntravenous20 mg/100ml
Solution, for slushIrrigation
InjectionIntravenous0.027 % w/v
CapsuleOral
EmulsionTopical
Capsule, delayed releaseOral
Capsule, extended releaseOral600 mg / cap
Capsule, extended releaseOral750 mg/1
Capsule, extended releaseOral600 mg/1
Capsule, extended releaseOral750 mg / src
LiquidBuccal
SprayBuccal
Powder, for solutionOral13.125 g
Powder, for solutionOral13.125 G
Injection, solution, concentrateOral
KitOral
Injection, solutionHemodialysis; Intravenous
Kit; solutionIntraocular; Irrigation
Granule, effervescentOral
Injection, emulsion; injection, solutionIntravenous
Injection, solution, concentrateIntravenous
EmulsionIntravenous0.3 g/l
EmulsionIntravenous
EmulsionIntravenous4 g
Solution, concentrateOral
SolutionIntraocular; Ophthalmic
SolutionIntraocular; Irrigation
SolutionExtracorporeal; Intrabiliary; Intracardiac
InjectionIntravenous
PowderOral238.33 g
LiquidOral
EmulsionIntravenous3 g
SolutionIntravenous0.225 g/L
IrrigantIrrigation
Injection, solutionIntravenous
InjectionIntravenous30 mg/100ml
Injection, solutionIntra-arterial
Solution
Powder, for solutionOral
Injection, solutionIntravenous
Injection, solutionParenteral
SolutionOral
SolutionParenteral
Injection, solution, concentrateIntravenous3 MEQ/ML
CapsuleOral750 mg/1
Capsule, coated, extended releaseOral10 meq/1
Capsule, coated, extended releaseOral8 meq/1
Capsule, extended releaseOral10 meq/1
Capsule, extended releaseOral8 meq/1
For solutionOral1.5 g/1.58g
For solutionOral1.5 g/1.54g
Injection
InjectionIntravenous10 meq/50mL
InjectionIntravenous10 meq/100mL
InjectionIntravenous14.9 mg/1mL
InjectionIntravenous150 g/1000mL
InjectionIntravenous20 meq/50mL
InjectionIntravenous20 meq/100mL
InjectionIntravenous29.8 mg/1mL
InjectionIntravenous40 meq/100mL
InjectionIntravenous7.45 mg/1mL
Injection, solutionIntravenous10 meq/100mL
Injection, solutionIntravenous14.9 g/1000mL
Injection, solutionIntravenous200 meq/1000mL
Injection, solutionIntravenous22.4 g/1000mL
Injection, solutionIntravenous29.8 g/1000mL
Injection, solutionIntravenous30 meq/100mL
Injection, solutionIntravenous400 meq/1000mL
Injection, solutionIntravenous7.46 g/1000mL
Injection, solution, concentrateIntravenous149 mg/1mL
Injection, solution, concentrateIntravenous2 meq/1mL
Injection, solution, concentrateParenteral14.9 g/100mL
LiquidOral40 meq/30mL
PowderOral20 meq/1.5g
Powder, for solutionOral1.5 g/1.74g
Powder, for solutionOral1.5 g/1
Powder, for solutionOral25 meq/1
SolutionOral1.3 meq/1mL
SolutionOral1.5 g/15mL
SolutionOral2.6 meq/1mL
SolutionOral20 meq/15mL
SolutionOral3 g/15mL
SolutionOral40 meq/15mL
TabletOral10 meq/1
TabletOral1125 mg/1
TabletOral1500 mg/1
TabletOral750 mg/1
Tablet, extended releaseOral1500 mg/1
Tablet, extended releaseOral8 meq/1
Tablet, film coated, extended releaseOral10 meq/1
Tablet, film coated, extended releaseOral600 mg/1
Tablet, film coated, extended releaseOral8 meq/1
SolutionIntravenous50 g/1000ml
SolutionIntravenous50.0 g/1000ml
SolutionIntravenous1.5 g/1000ml
SolutionIntravenous3.00 g/1000ml
PowderHemodialysis12.5 g / vial
PowderHemodialysis13 g / vial
PowderHemodialysis15.26 g / vial
PowderHemodialysis25 g / vial
PowderHemodialysis7.65 g / vial
TabletOral20 meq/1
CapsuleOral600 mg/1
SolutionIntravenous20 mEq / 10 mL
SolutionIntravenous200 mEq / 100 mL
SolutionIntravenous149 mg / mL
SolutionIntravenous2 mEq / mL
Powder, for solutionOral1.5 g/1.58g
LiquidIntravenous2 mEq / mL
SolutionIntravenous1.784 mg / mL
SolutionIntravenous2.384 mg / mL
LiquidIntravenous149 mg / mL
LiquidIntravenous14.9 mg / mL
LiquidIntravenous22.4 mg / mL
LiquidIntravenous29.8 mg / mL
LiquidIntravenous7.46 mg / mL
SolutionIntravenous250 mg/1ml
InjectionIntravenous746 mg/100ml
InjectionIntravenous746 mg/50ml
InjectionIntravenous1.49 g/50ml
SolutionOral500 mg/5ml
TabletOral600 mg
Tablet, extended releaseOral600 mg / tab
PowderHemodialysis6.2 g / pck
SolutionOral40 meq/30mL
TabletOral
KitHemodialysis
SolutionHemodialysis; Intravenous
InjectionIntravenous0.21 g/100ml
DoucheVaginal
SolutionIntravenous0.1 g/500ml
SolutionIrrigation; Topical
InjectionIntravenous0.33 g/1L
Injection, solutionIrrigation
LiquidOral10 %
SolutionBuccal; Oral; Topical
AerosolOral
Granule
SprayOral
Tablet, extended releaseOral600 mg/1
Injection, emulsionIntravenous14 g/1000ml
Injection, emulsionIntravenous0.28 g/1000ml
Injection, solutionParenteral
Powder, for solutionOral2.9 g
ConcentrateIntravenous drip
InjectionIntravenous7.45 g/100ml
SolutionIntravenous0.3675 g/1000ml
LiquidIntravenous150 mg / mL
EmulsionIntravenous0.74 g/L
TabletOral
LiquidIrrigation
SolutionIntravenous; Irrigation
SolutionIntravenous0.3 g
TabletOral500 mg
Syrup500 mg/5ml
SolutionIntravenous150 mg/1ml
Tablet, delayed releaseOral500 mg
ElixirOral500 mg/5ml
Prices
Unit descriptionCostUnit
Klor-Con 100 20meq Packets Box106.77USD box
Kay Ciel 30 20meq Packets Box58.99USD box
Rum-K-SF 15% Liquid 473ml Bottle45.98USD bottle
Klor-Con 30 25meq Packets Box36.99USD box
Colyte 240 gm Solution26.0USD bottle
Colyte-Flavored 240 gm Solution18.17USD bottle
K-Lor 20meq Packets1.92USD packet
K-lyte tablet eff1.43USD tablet
K-lyte-cl 25 meq tablet eff1.43USD tablet
Micro-K 10meq capsule1.41USD capsule
Micro-K 8meq capsule1.21USD capsule
Potassium cl 25 meq tablet eff0.94USD tablet
Micro-k 10 meq extencaps0.91USD each
Potassium Chloride CR 10meq capsule0.9USD capsule
Potassium Chloride CR 8meq capsule0.87USD capsule
K-Tabs 10meq Controlled Release Tabs0.68USD tab
K-tab er 10 meq tablet0.66USD tablet
Kaochlor-eff 20 meq tablet0.59USD tablet
K-tab 10 meq tablet sa0.58USD tablet
K-Lyte 25 meq Effervescent Tablet0.58USD tablet
Klor-con m20 tablet0.57USD tablet
Klor-Con/EF 25meq Effervescent Tabs0.57USD tab
Klor-Con 8meq Controlled Release Tabs0.56USD tab
Klor-Con M20 20meq Controlled Release Tabs0.55USD tab
Potassium Chloride Crys CR 20meq Controlled Release Tabs0.53USD tab
Potassium cl 20 meq tablet er0.52USD tablet
Potassium cl 20 meq tablet sa0.52USD tablet
Klor-con 10 meq tablet0.5USD tablet
Klor-con m15 tablet0.5USD tablet
Klotrix 10meq Controlled Release Tabs0.5USD tab
Potassium cl er 20 meq tablet0.49USD tablet
Klor-con-ef 25 meq tablet eff0.4USD tablet
Micro-k 8 meq extencaps0.34USD each
Kaon-Cl-10 10meq Controlled Release Tabs0.3USD tab
Klor-con m10 tablet0.3USD tablet
Potassium cl er 10 meq tablet0.3USD tablet
Potassium cl 10 meq tablet sa0.29USD tablet
Potassium Chloride Crys CR 10meq Controlled Release Tabs0.28USD tab
Potassium Chloride CR 10meq Controlled Release Tabs0.27USD tab
Potassium cl er 8 meq tablet0.26USD tablet
Kaon-cl 10 meq tablet sa0.23USD tablet
Potassium cl 2 meq/ml vial0.23USD ml
K-Dur 20 meq Sustained-Release Tablet0.21USD tablet
Potassium Chloride CR 8meq Controlled Release Tabs0.18USD tab
Klor-con 8 meq tablet0.16USD tablet
Slow K 8 meq Sustained-Release Tablet0.16USD tablet
Micro-K Extencaps 8 meq Sustained-Release Capsule0.1USD capsule
Apo-K 8 meq Sustained-Release Tablet0.09USD tablet
Potassium Chloride 40 Meq/15ml(20%) Liquid0.06USD ml
Potassium Chloride 20 Meq/15ml(10%) Liquid0.03USD ml
Potassium chloride crystals0.02USD g
K-10 Oral Liquid 1.33 meq/ml Liquid0.02USD ml
Colyte with flavor packets0.01USD ml
Pms - Potassium Chloride 1.33 meq/ml Liquid0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US7291324No2007-11-062022-10-22US flag
US7169381No2007-01-302024-09-01US flag
US7658914No2010-02-092024-09-01US flag
US7084130No2006-08-012021-11-29US flag
US9326969No2016-05-032033-09-10US flag
US9592252No2017-03-142032-08-11US flag
US9707297No2017-07-182033-09-10US flag
US8999313No2015-04-072033-09-10US flag
US10016504No2018-07-102033-09-10US flag
US10646512No2020-05-122032-03-25US flag
US10792306No2020-10-062032-03-09US flag
US10780112No2020-09-222032-03-09US flag
US10143656No2018-12-042037-08-04US flag
US10918723No2021-02-162033-09-10US flag
US11033498No2017-08-042037-08-04US flag

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)770 °CNot Available
water solubilityFreely solubleNot Available
Predicted Properties
PropertyValueSource
logP0.2ChemAxon
pKa (Strongest Acidic)-7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9445
Blood Brain Barrier+0.975
Caco-2 permeable+0.6764
P-glycoprotein substrateNon-substrate0.9039
P-glycoprotein inhibitor INon-inhibitor0.9891
P-glycoprotein inhibitor IINon-inhibitor0.9866
Renal organic cation transporterNon-inhibitor0.9219
CYP450 2C9 substrateNon-substrate0.8116
CYP450 2D6 substrateNon-substrate0.717
CYP450 3A4 substrateNon-substrate0.7571
CYP450 1A2 substrateNon-inhibitor0.7551
CYP450 2C9 inhibitorNon-inhibitor0.8594
CYP450 2D6 inhibitorNon-inhibitor0.9314
CYP450 2C19 inhibitorNon-inhibitor0.8365
CYP450 3A4 inhibitorNon-inhibitor0.9576
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9002
Ames testNon AMES toxic0.6808
CarcinogenicityCarcinogens 0.7523
BiodegradationReady biodegradable0.6815
Rat acute toxicity1.9786 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9433
hERG inhibition (predictor II)Non-inhibitor0.9634
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A2
Uniprot ID
P55011
Uniprot Name
Solute carrier family 12 member 2
Molecular Weight
131445.825 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. [Article]
  4. Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. [Article]
  5. Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. [Article]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
Gene Name
SLC12A5
Uniprot ID
Q9H2X9
Uniprot Name
Solute carrier family 12 member 5
Molecular Weight
126182.49 Da
References
  1. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. [Article]
  2. Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. [Article]
  3. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
  4. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. [Article]
  5. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Rubidium ion transmembrane transporter activity
Specific Function
Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.
Gene Name
SLC12A6
Uniprot ID
Q9UHW9
Uniprot Name
Solute carrier family 12 member 6
Molecular Weight
127615.745 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear....
Gene Name
SLC12A7
Uniprot ID
Q9Y666
Uniprot Name
Solute carrier family 12 member 7
Molecular Weight
119104.84 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
Gene Name
SLC12A4
Uniprot ID
Q9UP95
Uniprot Name
Solute carrier family 12 member 4
Molecular Weight
120648.73 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A2
Uniprot ID
P55011
Uniprot Name
Solute carrier family 12 member 2
Molecular Weight
131445.825 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. [Article]
  4. Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. [Article]
  5. Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. [Article]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
Gene Name
SLC12A5
Uniprot ID
Q9H2X9
Uniprot Name
Solute carrier family 12 member 5
Molecular Weight
126182.49 Da
References
  1. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. [Article]
  2. Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. [Article]
  3. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
  4. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. [Article]
  5. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Rubidium ion transmembrane transporter activity
Specific Function
Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.
Gene Name
SLC12A6
Uniprot ID
Q9UHW9
Uniprot Name
Solute carrier family 12 member 6
Molecular Weight
127615.745 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear....
Gene Name
SLC12A7
Uniprot ID
Q9Y666
Uniprot Name
Solute carrier family 12 member 7
Molecular Weight
119104.84 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
Gene Name
SLC12A4
Uniprot ID
Q9UP95
Uniprot Name
Solute carrier family 12 member 4
Molecular Weight
120648.73 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]

Drug created on June 13, 2005 13:24 / Updated on October 15, 2021 19:56